ATE529743T1 - Verfahren und kits zur tumorigenizitätsdiagnose - Google Patents

Verfahren und kits zur tumorigenizitätsdiagnose

Info

Publication number
ATE529743T1
ATE529743T1 AT03776580T AT03776580T ATE529743T1 AT E529743 T1 ATE529743 T1 AT E529743T1 AT 03776580 T AT03776580 T AT 03776580T AT 03776580 T AT03776580 T AT 03776580T AT E529743 T1 ATE529743 T1 AT E529743T1
Authority
AT
Austria
Prior art keywords
methods
kits
patient
concentration
tumorigenicity
Prior art date
Application number
AT03776580T
Other languages
English (en)
Inventor
Ginette Serrero
Original Assignee
A & G Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by A & G Pharmaceutical Inc filed Critical A & G Pharmaceutical Inc
Application granted granted Critical
Publication of ATE529743T1 publication Critical patent/ATE529743T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Food Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT03776580T 2002-10-28 2003-10-27 Verfahren und kits zur tumorigenizitätsdiagnose ATE529743T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/281,160 US7091047B2 (en) 1997-05-23 2002-10-28 Methods and kits for diagnosing tumorigenicity
PCT/US2003/034146 WO2004039244A2 (en) 2002-10-28 2003-10-27 Methods and kits for diagnosing tumorigenicity

Publications (1)

Publication Number Publication Date
ATE529743T1 true ATE529743T1 (de) 2011-11-15

Family

ID=32228759

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03776580T ATE529743T1 (de) 2002-10-28 2003-10-27 Verfahren und kits zur tumorigenizitätsdiagnose

Country Status (8)

Country Link
US (1) US7091047B2 (de)
EP (1) EP1563308B1 (de)
JP (2) JP4242836B2 (de)
AT (1) ATE529743T1 (de)
AU (2) AU2003284190B2 (de)
CA (1) CA2504178C (de)
ES (1) ES2395125T3 (de)
WO (1) WO2004039244A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100111928A1 (en) * 1997-05-23 2010-05-06 A & G Pharmaceutical, Inc. Methods and kits for diagnosis tumorgenicity
US8512960B2 (en) * 1997-05-23 2013-08-20 A&G Pharmaceutical, Inc. 88kDa tumorigenic growth factor and antagonists
US20030215445A1 (en) 1997-05-23 2003-11-20 Ginette Serrero Methods and compositions for inhibiting the growth of hematopoietic malignant cells
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US7411045B2 (en) * 2002-11-19 2008-08-12 A&G Pharmaceutical, Inc. Autocrine growth factor receptor antibodies and methods
JP4488903B2 (ja) * 2003-02-26 2010-06-23 エイアンドジー ファーマスーティカル インコーポレイテッド B細胞の増殖を増加させる方法
EP1849480A3 (de) * 2003-06-23 2013-06-26 A & G Pharmaceutical, Inc. Zusammensetzungen und Verfahren zur Wiederherstellung der Empfindlichkeit von Tumorzellen gegen die Antitumorbehandlung und zur Induzierung von Apoptose
US20070065887A1 (en) * 2003-07-21 2007-03-22 Kinch Michael S Diagnosis of pre-cancerous conditions using pcdgf agents
EP1660010B1 (de) * 2003-08-01 2013-07-24 A & G Pharmaceutical, Inc. Zusammensetzungen und verfahren zur wiederherstellung der empfänglichkeit für eine behandlung mit her2-antagonisten
AU2009289452A1 (en) * 2008-09-05 2010-03-11 A&G Pharmaceutical, Inc. Methods for diagnosing cancer and determining the overall survival and disease-free survival of cancer patients
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
SI3288379T1 (sl) 2015-05-01 2022-06-30 Onl Therapeutics, Inc. Peptidne sestave in načini uporabe
US20250154237A1 (en) * 2022-02-24 2025-05-15 A & G Pharmaceutical, Inc. Fully human monoclonal antibodies against human progranulin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5416192A (en) * 1990-04-03 1995-05-16 Bristol-Myers Squibb Company Epithelins: novel cysteine-rich growth modulating proteins
WO1993015195A1 (en) 1992-02-03 1993-08-05 Samuel Solomon Granulins from leukocytes
US6309826B1 (en) * 1997-05-23 2001-10-30 Ginette Serrero 88kDa tumorigenic growth factor and antagonists
US6881548B2 (en) * 1997-05-23 2005-04-19 A&G Pharmaceutical, Inc. Methods and kits for diagnosing tumorigenicity and determining resistance to the antineoplastic effects of antiestrogen therapy
ATE278421T1 (de) * 2000-08-11 2004-10-15 Wyeth Corp Verfahren zur behandlung eines östrogenrezeptor positives karzinoms
WO2009152607A1 (en) * 2008-06-16 2009-12-23 Ottawa Hospital Research Institute Methods and kits for diagnosing neurodegenerative disease

Also Published As

Publication number Publication date
EP1563308A2 (de) 2005-08-17
WO2004039244A2 (en) 2004-05-13
JP2006504104A (ja) 2006-02-02
EP1563308B1 (de) 2011-10-19
AU2003284190B2 (en) 2010-09-02
EP1563308A4 (de) 2006-11-29
JP2009109489A (ja) 2009-05-21
WO2004039244A3 (en) 2005-05-19
US7091047B2 (en) 2006-08-15
AU2010246504A1 (en) 2010-12-23
JP4242836B2 (ja) 2009-03-25
CA2504178C (en) 2020-12-15
AU2003284190A1 (en) 2004-05-25
US20030108950A1 (en) 2003-06-12
JP4763032B2 (ja) 2011-08-31
AU2010246504B2 (en) 2011-09-22
ES2395125T3 (es) 2013-02-08
CA2504178A1 (en) 2004-05-13

Similar Documents

Publication Publication Date Title
Sakharov et al. Relationship between lactate concentrations in active muscle sweat and whole blood
WO2004039244A3 (en) Methods and kits for diagnosing tumorigenicity
Tong et al. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison
ATE406834T1 (de) System zur überwachung der konzentration von analyten in körperflüssigkeiten
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
BRPI0718106B8 (pt) artigo absorvente selecionado de artigos absorventes de cuidados pessoais e artigos absorventes médicos, para receber urina suspeita de conter um analito
WO2003101277A3 (en) Noninvasive detection of a physiologic parameter within a body tissue of a patient
DE60011274D1 (de) Verfahren, reagenz und messkartusche zur bestimmung der gerinnungszeit
DE69230000D1 (de) Verfahren und testsatz zur messung von endogenen zytokinen
Kario et al. The influence of work-and home-related stress on the levels and diurnal variation of ambulatory blood pressure and neurohumoral factors in employed women
EP1162457A3 (de) Vielfach-Koagulationstestsystem und Verfahren zu seiner Anwendung
CN101025415A (zh) 一种检测尿液中尿酸含量范围的试纸
JP2006517670A5 (de)
WO2002061437A3 (en) Method and system for diagnosing andropause in males
ATE429440T1 (de) Formen prostataspezifischer antigene und verfahren zu deren nachweis
Reed et al. 70. Cortisol Response to Psychosocial Stress and Working Memory Performance in Schizophrenia
EP1804789A4 (de) Verfahren zur behandlung von präeklampsie beim menschen mit resibufagenin
Newton et al. Improvement in systemic endothelial condition following amputation in patients with critical limb ischemia
SU1247014A1 (ru) Способ диагностики болезни Вильсона-Коновалова
MD2095G2 (ro) Metodă de diagnosticare a funcţiei pancreasului la copii cu afecţiuni gastroduadenale cronice
UA28780U (en) Method for diagnosing and assessing activity of inflammation in diseases of periodontium
Yu et al. Determination of CKMB activity and protein concentration and their application in the diagnosis of AMI
SU1431739A1 (ru) Способ определени индивидуальной чувствительности к протеолитическим ферментам при лечении рассе нного склероза
RU2237250C2 (ru) Способ лабораторного неинвазивного подтверждения иммуноглобулин-e (ige)-зависимого генеза сезонного риноконъюнктивита (срк) у детей
Edyvane et al. Does the bladder mucosa contribute to urinary inhibitory activity?

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties